The BIOSECURE Act is driving a historic shift in peptide API manufacturing away from Asia. An estimated $3.1 billion in reshoring-related peptide manufacturing investment has been announced or committed across North America and Europe since January 2025.
Source: PeptideStaff
Major Investments
- Thermo Fisher — $420M expansion in Greenville, North Carolina (announced March 2026)
- Recipharm — $180M expansion at Niagara Falls facility for lyophilization and fill-finish capacity
- Bachem — Sisseln campus expansion in Switzerland
- Lonza — continued investment in Visp, Switzerland
- Neuland Laboratories — $30M commercial-scale peptide facility in India
North American peptide API manufacturing capacity is expected to grow from approximately 18% of global capacity in 2024 to an estimated 28% by 2029. However, domestic manufacturing carries a 35–65% cost premium over established Asian suppliers.
The single most underappreciated constraint on reshoring timelines is workforce. Experienced peptide manufacturing personnel in North America and Europe are scarce relative to the scale of investment being made. Industry analysts warn of a critical 18–36 month capacity gap between decommissioning Asian supply relationships and the availability of validated domestic alternatives.